About Zymeworks (NYSE:ZYME)
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$51.76 million
Price / Sales5.87
Price / CashN/A
Book Value$4.59 per share
Price / Book2.60
EPS (Most Recent Fiscal Year)($0.57)
Return on Equity-12.37%
Return on Assets-8.32%
Zymeworks (NYSE:ZYME) Frequently Asked Questions
What is Zymeworks' stock symbol?
Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."
How were Zymeworks' earnings last quarter?
Zymeworks (NYSE:ZYME) announced its earnings results on Wednesday, March, 14th. The company reported $1.28 earnings per share (EPS) for the quarter. The business had revenue of $50.07 million for the quarter. Zymeworks had a negative net margin of 20.10% and a negative return on equity of 12.37%. View Zymeworks' Earnings History.
When is Zymeworks' next earnings date?
What price target have analysts set for ZYME?
6 brokers have issued twelve-month target prices for Zymeworks' stock. Their forecasts range from $8.00 to $20.00. On average, they anticipate Zymeworks' share price to reach $16.40 in the next twelve months. View Analyst Ratings for Zymeworks.
Who are some of Zymeworks' key competitors?
Some companies that are related to Zymeworks include Rhythm Pharmaceuticals (RYTM), Arrowhead Pharmaceuticals (ARWR), BeyondSpring (BYSI), Geron (GERN), Odonate Therapeutics (ODT), Reata Pharmaceuticals (RETA), Five Prime Therapeutics (FPRX), Clementia Pharmaceuticals (CMTA), Kura Oncology (KURA), Keryx Biopharmaceuticals (KERX), Aduro BioTech (ADRO), AC Immune (ACIU), Rigel Pharmaceuticals (RIGL), Achaogen (AKAO), TiGenix - American Depositary Shares (TIG), Akebia Therapeutics (AKBA), Dicerna Pharmaceuticals (DRNA) and Aclaris Therapeutics (ACRS).
Who are Zymeworks' key executives?
Zymeworks' management team includes the folowing people:
- Dr. Ali Tehrani Ph.D., Co-Founder, Chief Exec. Officer, Pres and Director (Age 46)
- Mr. Neil Klompas CPA, CA, Chief Financial Officer (Age 46)
- Dr. Diana F. Hausman M.D., Chief Medical Officer (Age 55)
- Dr. Donald L. Drakeman Ph.D., J.D., Special Advisor (Age 64)
- Mr. David Tucker, Chief Operating Officer
When did Zymeworks IPO?
(ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.
Has Zymeworks been receiving favorable news coverage?
Media stories about ZYME stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zymeworks earned a news sentiment score of 0.16 on Accern's scale. They also gave media headlines about the company an impact score of 44.88 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Zymeworks?
Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zymeworks' stock price today?
One share of ZYME stock can currently be purchased for approximately $11.93.
How big of a company is Zymeworks?
Zymeworks has a market capitalization of $317.11 million and generates $51.76 million in revenue each year. The company earns $-10,400,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Zymeworks employs 147 workers across the globe.
How can I contact Zymeworks?
Zymeworks' mailing address is 1385 West 8th Avenue Suite 540, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]
MarketBeat Community Rating for Zymeworks (ZYME)MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe ZYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
Zymeworks (NYSE:ZYME) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Zymeworks (NYSE ZYME) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 7.27%
Zymeworks (NYSE ZYME) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
Zymeworks (NYSE ZYME) News Headlines
Zymeworks (NYSE:ZYME) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Zymeworks (NYSE:ZYME) Income Statement, Balance Sheet and Cash Flow Statement
Zymeworks (NYSE ZYME) Stock Chart for Friday, April, 20, 2018